Senores FY26 PAT Surges 108%; Targets 30-40% Revenue Growth
Senores Pharmaceuticals reported strong FY26 results with PAT growing 108% YoY to Rs 122 crores and revenue increasing 62% to Rs 664 crores. The company guided for 30-40% revenue growth and 50-60% profit growth in FY27, supported by an expanded ANDA pipeline and strategic acquisitions including Apnar Pharmaceuticals and Zoraya Pharmaceuticals.
*this image is generated using AI for illustrative purposes only.
Senores Pharmaceuticals reported a strong financial performance for the year ended March 31, 2026, with significant growth in revenue and profitability across all key segments. The Board of Directors approved the audited consolidated and standalone financial results for the quarter and financial year ended March 31, 2026, at its meeting held on May 14, 2026. Subsequently, the company issued a corrigendum correcting certain segmental revenue figures, year-on-year growth rates, and prior year comparatives that contained a typing error in the original media release. The statutory auditors, M/s. Pankaj R. Shah and Associates, issued an unmodified opinion on the financial statements. In compliance with Regulations 30 and 46 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company also held an Earnings Conference Call with analysts, institutional investors, funds, and other investors on May 14, 2026, with the audio recording now available on the company's website at senorespharma.com/investor-meet/ . The company confirmed that no Unpublished Price Sensitive Information was shared or discussed during the call.
FY27 Outlook
Senores Pharmaceuticals has guided for a revenue growth estimate of 30-40% for FY27, along with approximately 50-60% profit growth for the same period. This forward-looking guidance reflects the company's confidence in sustaining its growth trajectory, backed by an expanding ANDA pipeline, new acquisitions, and strengthened market access across regulated and emerging markets.
FY26 Financial Performance
For the full year FY26, the company reported total income of Rs. 664 crores, a 62% year-on-year increase. EBITDA for FY26 stood at Rs. 200 crores, surging 96% year-on-year. Net profit after tax (PAT) for the year stood at Rs. 122 crores, marking a 108% year-on-year growth. Earnings per share (EPS) for the year increased to ₹26.39 from ₹16.12 in the prior year. Cash Flow from Operations for FY26 stood at Rs. 75 crores, showing significant improvement over the previous year.
Q4FY26 Highlights
The fourth quarter of FY26 also demonstrated robust momentum. Total income for Q4FY26 reached Rs. 190 crores, up 58% year-on-year. EBITDA for the quarter surged 144% year-on-year to Rs. 62 crores. PAT for Q4FY26 rose to Rs. 37 crores, reflecting 105% year-on-year growth.
The following table presents the consolidated financial highlights for FY26 and Q4FY26:
| Metric: | FY26 | FY25 | Y-o-Y |
|---|---|---|---|
| Total Income | Rs. 664 crores | Rs. 410.4 crores | +62% |
| EBITDA | Rs. 200 crores | — | +96% |
| PAT | Rs. 122 crores | — | +108% |
| EPS | ₹26.39 | ₹16.12 | — |
| Metric: | Q4FY26 | Q4FY25 | Y-o-Y |
|---|---|---|---|
| Total Income | Rs. 190 crores | — | +58% |
| EBITDA | Rs. 62 crores | — | +144% |
| PAT | Rs. 37 crores | — | +105% |
Segmental Performance
The company's regulated markets segment was the standout performer, with revenue growing 74.6% for FY26 and 83.0% in Q4FY26. The branded generics business surged 385.3% year-on-year for FY26, with the portfolio receiving approvals from top multi-specialty and specialty hospitals. The emerging markets business maintained a steady trajectory, growing approximately 13% year-on-year for FY26, with EBITDA margin at approximately 12%.
The corrected segmental revenue figures, as per the corrigendum issued by the company, are presented below:
| Segment Revenue (INR Cr): | Q4FY26 | Q4FY25 | Y-o-Y | FY26 | FY25 | Y-o-Y |
|---|---|---|---|---|---|---|
| Regulated Markets | 117.8 | 64.3 | +83.0% | 427.4 | 244.8 | +74.6% |
| Emerging Markets | 45.9 | 36.5 | +25.8% | 145.0 | 121.2 | +19.7% |
| Branded Generics | 9.4 | 4.0 | +132.4% | 40.0 | 8.2 | +385.3% |
| Others | 16.6 | 15.3 | +8.8% | 51.6 | 36.2 | +42.7% |
| Total Income | 189.7 | 120.1 | +57.9% | 664.0 | 410.4 | +61.8% |
Strategic & Operational Highlights
Senores expanded its regulated markets pipeline significantly, with 51 approved ANDAs covering 151 strengths as of March 2026, up from 26 ANDAs as of March 2025. Over 30 of these approved ANDAs are yet to be commercialized, and 27 additional ANDAs covering 65+ strengths are under development. The company completed Phase 1 of the acquisition of a 75% equity stake in Apnar Pharmaceuticals, with Phase 2 (balance 25%) expected to be completed by Q2FY27. Initial revenues from the Apnar facility commenced in Q4FY26, with scale-up to peak revenue expected over the next 12–18 months.
| Strategic Initiative: | Details |
|---|---|
| Apnar Pharmaceuticals Acquisition | Phase 1 (75% stake) completed; Phase 2 (25%) by Q2FY27 |
| Zoraya Pharmaceuticals Acquisition | 51% membership interest in USA-based entity acquired |
| Amerisyn JV | 70% joint venture for U.S. federal, veterans, and defense market access |
| Approved ANDAs | 51 ANDAs covering 151 strengths |
| ANDAs Under Development | 27 molecules with 65+ strengths |
In addition to the Apnar acquisition, the company entered into an agreement to acquire a 51% membership interest in Zoraya Pharmaceuticals, LLC, a USA-based entity, to strengthen vertical integration and direct commercialization of its ANDA portfolio. In April 2026, Senores entered into a 70% joint venture, Amerisyn, in the U.S., creating a direct pathway to supply pharmaceuticals to federal, veterans, and defense sectors.
Management Commentary
Commenting on the FY26 performance, Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited, said: "We have delivered a robust performance across segments in FY26, driven by operational discipline, consistent execution, and strong momentum in key growth areas despite an uncertain operating environment. Our approved ANDA portfolio has more than doubled during the year, increasing from 26 ANDAs as of March 2025 to 51 ANDAs as of March 2026, reflecting the scale and pace of our execution. We have expanded our manufacturing footprint and product portfolio through acquisition of Apnar Pharmaceuticals, which enhances scalability, deepens access to Regulated Markets, and expands CDMO-CMO opportunities. All in all, we continue to outperform on our stated commitments despite an uncertain environment, reflecting the strength of our long-term strategy, diversified business verticals and disciplined execution."
Corporate Governance Updates
During the board meeting, the company approved the resignation of Mr. Vinay Kumar Mishra as Company Secretary and Compliance Officer, effective from the close of business hours on June 10, 2026. Based on the Audit Committee's recommendation, the Board appointed Sharp & Tannan Associates, Chartered Accountants, as the Internal Auditor of the company for FY 2026-27.
Historical Stock Returns for Senores Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +1.12% | -9.53% | +16.23% | +31.63% | +101.70% | +87.61% |
How might the Zoraya Pharmaceuticals acquisition and Amerisyn JV collectively accelerate Senores' direct commercialization capabilities in the U.S. market, and what revenue contribution can investors realistically expect from these ventures in FY27?
With over 30 approved ANDAs yet to be commercialized, what factors—such as pricing pressure, competition, or supply chain readiness—could determine the pace and profitability of their launch over the next 12–18 months?
Given the branded generics segment's explosive 385% growth in FY26 from a relatively small base, how sustainable is this trajectory, and which therapeutic areas or hospital networks could drive the next phase of expansion?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
